Seeking Alpha
 

Zoetis (ZTS)

- NYSE
  • Tue, Aug. 4, 11:01 AM
    • Zoetis (ZTS +0.72%) Q2 results: Revenues: $1,175M (+1.5%); COGS: $427M (+3.4%); R&D Expense: $84M (-8.7%); SG&A: $379M (-4.3%); Net Loss: ($37M) (-127.2%); Loss Per Share: ($0.07) (-125.9%).
    • 2015 Guidance: Revenue: $4,700M - 4,775M; Adjusted SG&A Expenses: $1,355M - 1,405M; Adjusted R&D Expenses: $380M - 400M; Adjusted interest expense and other (income)/deductions: ~110M (unch); Adjusted diluted EPS: $1.63 - 1.68; Adjusted net income: $820M - 845M; Reported diluted EPS: $0.81 - 1.02; Reported net income: $410M - 515M.
    • 2016 Guidance: Revenue: $4,650M - 4,800M; Adjusted SG&A Expenses: $1,270M - 1,340M; Adjusted R&D Expenses: $380M - 400M; Adjusted EPS: $1.81 - 1.93; Adjusted net income: $910M - 970M; Reported EPS: $1.45 - 1.65; Reported net income: $730M - 830M.
    • 2017 Guidance: Revenue: $4,850M - 5,050M; Adjusted SG&A Expenses: $1,240M - 1,330M; Adjusted R&D Expenses: $380M - 400M; Adjusted EPS: $2.18 - 2.32; Adjusted net income: $1,095M - 1,165M; Reported EPS: $1.98 - 2.16; Reported net income: $995M - 1,085M.
    | Tue, Aug. 4, 11:01 AM | Comment!
  • Tue, Aug. 4, 7:04 AM
    • Zoetis (NYSE:ZTS): Q2 EPS of $0.43 beats by $0.05.
    • Revenue of $1.18B (+1.7% Y/Y) beats by $60M.
    • Press Release
    | Tue, Aug. 4, 7:04 AM | Comment!
  • Mon, Aug. 3, 11:25 AM
    • Zoetis (ZTS -0.2%) will report Q2 results tomorrow before the open. Consensus view is EPS of $0.38 (+41%) on revenues of $1.1B (0%).
    | Mon, Aug. 3, 11:25 AM | Comment!
  • Tue, May 5, 9:45 AM
    • Zoetis (ZTS +2.4%) Q1 results: Revenues: $1,102M (+0.5%), Livestock: $715M (+1.3%), Companion Animal: $377M (-0.8%), Contract Manufacturing: $10M (-9.1%); COGS: $394M (+4.0%); R&D Expense: $80M (-8.0%); SG&A: $354M (-0.6%); Net Income: $165M (+6.5%); EPS: $0.33 (+6.5%).
    • 2015 Guidance: Revenue: $4,675M - 4,775M from $4,800M - 4,900M; Adjusted SG&A Expenses: $1,355M - 1,405M from $1,420M - 1,470M; Adjusted R&D Expenses: $380M - 400M from $385M - 405M; Adjusted interest expense and other (income)/deductions: ~110M (unch); Adjusted diluted EPS: $1.61 - 1.68 (unch); Adjusted net income: $810M - 845M (unch); Reported diluted EPS: $0.79 - 1.02 from $1.32 - 1.39; Reported net income: $400M - 515M.
    • 2016 Guidance: Revenue: $4,650M - 4,800M; Adjusted SG&A Expenses: $1,270M - 1,340M; Adjusted R&D Expenses: $380M - 400M; Adjusted EPS: $1.81 - 1.93; Adjusted net income: $910M - 970M; Reported EPS: $1.45 - 1.65; Reported net income: $730M - 830M.
    • 2017 Guidance: Revenue: $4,850M - 5,050M; Adjusted SG&A Expenses: $1,240M - 1,330M; Adjusted R&D Expenses: $380M - 400M; Adjusted EPS: $2.18 - 2.32; Adjusted net income: $1,095M - 1,165M; Reported EPS: $1.98 - 2.16; Reported net income: $995M - 1,085M.
    | Tue, May 5, 9:45 AM | Comment!
  • Tue, May 5, 7:02 AM
    • Zoetis (NYSE:ZTS): Q1 EPS of $0.41 beats by $0.04.
    • Revenue of $1.1B (flat Y/Y) misses by $10M.
    • Press Release
    | Tue, May 5, 7:02 AM | Comment!
  • Wed, Feb. 11, 8:02 AM
    • Zoetis (NYSE:ZTS) Q4 results ($M): Revenues: 1,320 (+5.3%); Livestock: 904 (+7.1%); Companion Animal: 405 (+2.8%); Operating Expenses: 621 (+7.3%); Net Income: 126 (+20.0%); EPS: 0.25 (+19.0%).
    • 2015 Guidance: Revenues: $4.8B - 4.9B; Non-GAAP Net Income: $810M - 845M; EPS: $1.32 - 1.39; Non-GAAP EPS: $1.61 - 1.68.
    | Wed, Feb. 11, 8:02 AM | 1 Comment
  • Wed, Feb. 11, 7:02 AM
    • Zoetis (NYSE:ZTS): Q4 EPS of $0.40 beats by $0.04.
    • Revenue of $1.32B (+5.6% Y/Y) beats by $50M.
    • Press Release
    | Wed, Feb. 11, 7:02 AM | Comment!
  • Tue, Feb. 10, 5:30 PM
  • Dec. 31, 2014, 10:39 AM
    • Zoetis (ZTS +0.5%) will report Q4 and full-year results on February 11 before the open. The conference call will begin at 8:30 am ET.
    • Consensus views for Q4 and 2014 are EPS of $0.36 and $1.54 on revenues of $1.3B and $4.8B, respectively.
    | Dec. 31, 2014, 10:39 AM | Comment!
  • Nov. 4, 2014, 7:02 AM
    • Zoetis (NYSE:ZTS): Q3 EPS of $0.41 beats by $0.04.
    • Revenue of $1.2B (+9.1% Y/Y) beats by $40M.
    • Press Release
    | Nov. 4, 2014, 7:02 AM | Comment!
  • Sep. 30, 2014, 9:17 AM
    • Zoetis (NYSE:ZTS) will report Q3 results on November 4 before the open.
    • Consensus view is EPS of $0.37 on revenues of $1.16B.
    | Sep. 30, 2014, 9:17 AM | Comment!
  • Aug. 5, 2014, 7:20 AM
    • Zoetis (NYSE:ZTS) Q2 results: $1,158M (+3.9%); Gross Profit: $745M (+6.7%); Operating Income: $139M (-25.7%); Net Income: $136M (+6.3%); EPS: $0.27 (+3.8%).
    • 2014 Guidance: Revenue: $4.675B - 4.750B; GAAP EPS: $1.16 - 1.20; non-GAAP EPS: $1.50 - 1.54.
    | Aug. 5, 2014, 7:20 AM | Comment!
  • Aug. 5, 2014, 7:04 AM
    • Zoetis (NYSE:ZTS): Q2 EPS of $0.38 in-line.
    • Revenue of $1.16B (+4.5% Y/Y) in-line.
    • Press Release
    | Aug. 5, 2014, 7:04 AM | Comment!
  • May 6, 2014, 10:41 AM
    • Zoetis (ZTS +1.4%) Total revenue: $1.1B (+0.6%); Livestock: $706M (+0.4%); Companion Animal: $380M (+1.1%); Contract Manufacturing: $11M (unch); operating income: $362M (+9.4%); net income: $155M (+10.7%); EPS: $0.31 (+10.7%).
    • 2014 guidance: revenue: $4.65B - 4.75B; COGS: ~35.5%; EPS: $1.15 - 1.21.
    | May 6, 2014, 10:41 AM | Comment!
  • May 6, 2014, 7:06 AM
    • Zoetis (ZTS): Q1 EPS of $0.38 beats by $0.01.
    • Revenue of $1.1B (+0.9% Y/Y) misses by $30M.
    • Press Release
    | May 6, 2014, 7:06 AM | Comment!
  • Feb. 11, 2014, 7:57 AM
    • Zoetis (ZTS) swings to a net profit of $105M from a loss of $10M a year earlier.
    • The latest figure includes $75M for purchase accounting adjustments, acquisition-related costs and certain significant items.
    • Revenue breakdown: U.S. +7% to $516M; EMEA +9% to $330M; Canada/Latin America +8% to $223M; Asia/Pacific +14% to $185M.
    • Expects 2014 EPS of $1.48-1.54 vs consensus of $1.62 and revenues of $4.65-4.75B vs $4.77B. (PR)
    • Previous
    | Feb. 11, 2014, 7:57 AM | Comment!
Visit Seeking Alpha's
ZTS vs. ETF Alternatives
Company Description
Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives & other pharmaceutical products.